TY - JOUR AU - Yang Wen-sheng AU - Wang Jing-lin AU - Wu Wei AU - Wang Guang-fei AU - Yan Jun AU - Liu Qing AU - Wu Xiao-yan AU - Zhou Qing-tong AU - Yang De-hua AU - Wang Ming-Wei AU - Li Zhi-ping PY - 2022 TI - Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease JF - Acta Pharmacologica Sinica; Vol 44, No 1 (January 2023): Acta Pharmacologica Sinica Y2 - 2022 KW - N2 - Inflammatory bowel disease (IBD) is a global health burden whose existing treatment is largely dependent on anti-inflammatory agents. Despite showing some therapeutic actions, their clinical efficacy and adverse events are unacceptable. Resolution as an active and orchestrated phase of inflammation involves improper inflammatory response with three key triggers, specialized pro-resolving mediators (SPMs), neutrophils and phagocyte efferocytosis. The formyl peptide receptor 2 (FPR2/ALX) is a human G protein-coupled receptor capable of binding SPMs and participates in the resolution process. This receptor has been implicated in several inflammatory diseases and its association with mouse model of IBD was established in some resolution-related studies. Here, we give an overview of three reported FPR2/ALX agonists highlighting their respective roles in pro-resolving strategies. UR - http://www.chinaphar.com/article/view/10736